I-Mab Biopharma - Crunchbase Company Profile & Funding

Q: Where is I-Mab Biopharma's headquarters?

I-Mab Biopharma is located in Shanghai, Shanghai, China.

Q: Who invested in I-Mab Biopharma?

I-Mab Biopharma has 27 investors including Exome Asset Management And Adage Capital Management.

Q: When was the last funding round for I-Mab Biopharma?

I-Mab Biopharma closed its last funding round on obfuscated from a Post-IPO Equity round.

Q: How much funding has I-Mab Biopharma raised to date?

I-Mab Biopharma has raised obfuscated.

Overview

I-Mab Biopharma

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About I-Mab Biopharma

CB Rank

89810

I-Mab is a dynamic and fast-growing global biotech company exclusively focused on developing innovative biologics.

Founded

obfuscation

Public

Post-IPO Equity

Shanghai, Shanghai, China

11-50

www.i-mabbiopharma.com/

Biotechnology

Pharmaceutical

Product Research

Funding Rounds

Post-IPO Equity

OBF

obfuscation

Post-IPO Equity

OBF

obfuscation

Series C

OBF

obfuscation

Key People

Jingwu Zang: Chairman and CEO
Weimin Tang: Chief Business Officer
Past Role: Hengrui Therapeutics, Executive Director, Global Business Development & Licensing

Details

Legal Name

I-Mab Biopharma (Shanghai) Co., Ltd.

Also Known As

Tianzhenshi Biotechnology Company, 天境生物 , Tianjing Shengwu, 天境生物科技（上海）有限公司

Operating Status

Active

Stock Symbol

NASDAQ:IMAB

Company Type

For Profit

Founders

Jingwu Zang

About the Company

I-MAB is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. .

Phone Number

+862160578000

Contact Email

marcom@i-mabbiopharma.com

Predictions & Insights

Growth Insight

See this Growth Insight

I-Mab Biopharma is

Lorem

to be growing

Top Contributing Factors

Operations Contraction

Products & Services

Felzartamab (TJ202/MOR202)

A human monoclonal antibody targeting CD38 for treatment of multiple myeloma by recruiting immune cells to kill tumor cells via ADCC and ADCP mechanisms.

TJ-L14B/ABL503

A bispecific antibody targeting PD-L1 and 4-1BB designed to activate T cells conditionally in the presence of PD-L1 expressing tumor cells to treat resistant solid tumors.

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Post-IPO Equity - I-Mab Biopharma	4	obfuscated obfuscation	Everest Medicines	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - I-Mab Biopharma	4	obfuscated obfuscation	Everest Medicines	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - I-Mab Biopharma	4	obfuscated obfuscation	Everest Medicines	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - I-Mab Biopharma	4	obfuscated obfuscation	Everest Medicines	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - I-Mab Biopharma	4	obfuscated obfuscation	Everest Medicines	Post-IPO Equity

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Post-IPO Equity - I-Mab Biopharma	4	obfuscated obfuscation	Everest Medicines	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - I-Mab Biopharma	4	obfuscated obfuscation	Everest Medicines	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - I-Mab Biopharma	4	obfuscated obfuscation	Everest Medicines	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - I-Mab Biopharma	4	obfuscated obfuscation	Everest Medicines	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - I-Mab Biopharma	4	obfuscated obfuscation	Everest Medicines	Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Exome Asset Management	—	Post-IPO Equity - I-Mab Biopharma	—
Exome Asset Management	—	Post-IPO Equity - I-Mab Biopharma	—
Exome Asset Management	—	Post-IPO Equity - I-Mab Biopharma	—
Exome Asset Management	—	Post-IPO Equity - I-Mab Biopharma	—
Exome Asset Management	—	Post-IPO Equity - I-Mab Biopharma	—